TotalMarketCap

Anbio Biotechnology

NNNNNasdaq GermanyHealth CareBiotechnology: In Vitro & In Vivo Diagnostic Substances

Market cap

$529.520 M

$3.68 +0.00%

Close of 6 Nov 2026

As of 6 Nov 2026, Anbio Biotechnology (NNNN) has a market capitalization of $529.5M. Market cap measures the value of outstanding equity at market prices; company totals combine applicable share classes. Prices and market caps come from Nasdaq, with financial fundamentals from SEC filings. See sources and calculation details.

Revenue

$8.65M

#3165 by revenue

Earnings

$6.40M

#2123 by earnings

Shares outstanding

—

Latest filing cover page

P/E ratio

82.7

Cap ÷ net income

Biotechnology: In Vitro & In Vivo Diagnostic Substances, ranked by market cap

All 19 →
  1. #8Achieve Life SciencesACHV$658.1M
  2. #9Myriad GeneticsMYGN$597.3M
  3. #10Anbio BiotechnologyNNNN$529.5M
  4. #11Alpha TeknovaTKNO$484.9M
  5. #12ImmucellICCC$89.7M

What if Anbio Biotechnology were worth as much as…

Open the what-if tool →

Gold $28.2T

$196,237.67

Per share 53,325× higher

Bitcoin $1.53T

$10,618.08

Per share 2,885× higher

Apple $5.02T

$34,858.16

Per share 9,472× higher

Or at a round number

$1.00B$2.00B$5.00B$10.0B

Where these numbers come from

Share counts and financials for Anbio Biotechnology are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Read the methodology.